Journal of Shanghai Jiao Tong University (Medical Science) >
Hematopoietic imbalance-mediated ventricular remodeling after myocardial infarction: roles of immune cell subsets and emerging therapeutic strategies
Received date: 2025-08-04
Accepted date: 2025-09-22
Online published: 2025-12-12
Supported by
National Natural Science Foundation of China(82270350，82425060，82300381，82300326);Fundamental Research Funds for the Central Universities(22120220162);Shanghai Science and Technology Development Funds (Yangfan Special Project)(23YF1434800)
Ventricular remodeling following myocardial infarction (MI) and its associated myocardial fibrosis represent a core pathological mechanism in the progression of heart failure. Accumulating evidence confirms that the spatiotemporal dynamics of immune cells play a crucial role in post-MI ventricular remodeling, spanning the entire process of cardiac inflammation, tissue repair, and fibrosis. MI not only triggers a local inflammatory response but also remotely regulates hematopoietic organs such as the bone marrow and spleen via pathways including inflammatory factor release and sympathetic nervous system activation. This drives hematopoietic stem/progenitor cells (HSPCs) to differentiate with a bias toward the myeloid lineage, resulting in a hematopoietic imbalance phenomenon described as "myeloid upsurge-lymphoid decline". This imbalance is characterized by excessive proliferation and release of proinflammatory myeloid cells, such as neutrophils and monocytes/macrophages, alongside a relative reduction in lymphoid cells like T cells and B cells. This systemic immune imbalance reshapes the immune cell composition in the heart and peripheral organs. It exacerbates sustained cardiac inflammation, oxidative stress, cell apoptosis, and excessive extracellular matrix deposition, ultimately leading to aggravated cardiac fibrosis, ventricular dilation, and systolic function deterioration. It is a key driver of adverse post-MI remodeling and the onset of heart failure. This article aims to systematically explore the spatiotemporal dynamics and functional characteristics of immune cell subsets driven by this post-MI hematopoietic imbalance. Furthermore, it proposes novel intervention strategies focused on precisely modulating hematopoietic stem cell differentiation pathway and key immune cell subsets. These strategies aim to improve the cardiac inflammatory microenvironment, delay the fibrotic process, and inhibit adverse ventricular remodeling, thereby offering potential therapeutic targets for preventing and treating post-MI heart failure.
JIANG Kai , XU Yue , YANG Xingbo , WANG Dandan , XIANG Yaozu . Hematopoietic imbalance-mediated ventricular remodeling after myocardial infarction: roles of immune cell subsets and emerging therapeutic strategies[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(12) : 1644 -1653 . DOI: 10.3969/j.issn.1674-8115.2025.12.010
| [1] | ANDERSON J L, MORROW D A. Acute myocardial infarction[J]. N Engl J Med, 2017, 376(21): 2053-2064. |
| [2] | KRITTANAWONG C, KHAWAJA M, TAMIS-HOLLAND J E, et al. Acute myocardial infarction: etiologies and mimickers in young patients[J]. J Am Heart Assoc, 2023, 12(18): e029971. |
| [3] | SQUIRE I B, SZE S. Prognosis following acute myocardial infarction[J]. Eur Heart J, 2025, 46(16): 1551-1553. |
| [4] | FRANGOGIANNIS N G. The inflammatory response in myocardial injury, repair, and remodelling[J]. Nat Rev Cardiol, 2014, 11(5): 255-265. |
| [5] | JIANG K, HWA J, XIANG Y Z. Novel strategies for targeting neutrophil against myocardial infarction[J]. Pharmacol Res, 2024, 205: 107256. |
| [6] | KING K R, AGUIRRE A D, YE Y X, et al. IRF3 and type Ⅰ interferons fuel a fatal response to myocardial infarction[J]. Nat Med, 2017, 23(12): 1481-1487. |
| [7] | PEET C, IVETIC A, BROMAGE D I, et al. Cardiac monocytes and macrophages after myocardial infarction[J]. Cardiovasc Res, 2020, 116(6): 1101-1112. |
| [8] | SWIRSKI F K, NAHRENDORF M. Cardioimmunology: the immune system in cardiac homeostasis and disease[J]. Nat Rev Immunol, 2018, 18(12): 733-744. |
| [9] | XU Y, JIANG K, CHEN F, et al. Bone marrow-derived na?ve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin[J]. Basic Res Cardiol, 2022, 117(1): 47. |
| [10] | FRANGOGIANNIS N G. Chemokines in the ischemic myocardium: from inflammation to fibrosis[J]. Inflamm Res, 2004, 53(11): 585-595. |
| [11] | YANG S, PENNA V, LAVINE K J. Functional diversity of cardiac macrophages in health and disease[J]. Nat Rev Cardiol, 2025, 22(6): 431-442. |
| [12] | HOFMANN U, FRANTZ S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction[J]. Circ Res, 2015, 116(2): 354-367. |
| [13] | ZOUGGARI Y, AIT-OUFELLA H, BONNIN P, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction[J]. Nat Med, 2013, 19(10): 1273-1280. |
| [14] | NESTOROWA S, HAMEY F K, PIJUAN SALA B, et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation[J]. Blood, 2016, 128(8): e20-31. |
| [15] | HEUSCH G, KLEINBONGARD P. The spleen in ischaemic heart disease[J]. Nat Rev Cardiol, 2025, 22(7): 497-509. |
| [16] | LV H Z, WANG C C, LIU Z N, et al. Suppression of the prostaglandin I2-type 1 interferon axis induces extramedullary hematopoiesis to promote cardiac repair after myocardial infarction[J]. Circulation, 2025, 151(24): 1730-1747. |
| [17] | NINH V K, CALCAGNO D M, YU J D, et al. Spatially clustered type Ⅰ interferon responses at injury borderzones[J]. Nature, 2024, 633(8028): 174-181. |
| [18] | CHEN R K, ZHANG H R, TANG B T, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets[J]. Signal Transduct Target Ther, 2024, 9(1): 130. |
| [19] | JIANG K, TU Z Z, CHEN K, et al. Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction[J]. J Clin Invest, 2022, 132(1): e151268. |
| [20] | SHI J J, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575): 660-665. |
| [21] | CALCAGNO D M, ZHANG C, TOOMU A, et al. SiglecFHI marks late-stage neutrophils of the infarcted heart: a single-cell transcriptomic analysis of neutrophil diversification[J]. J Am Heart Assoc, 2021, 10(4): e019019. |
| [22] | PFIRSCHKE C, ENGBLOM C, GUNGABEESOON J, et al. Tumor-promoting ly-6G+ SiglecFhigh cells are mature and long-lived neutrophils[J]. Cell Rep, 2020, 32(12): 108164. |
| [23] | ENGBLOM C, PFIRSCHKE C, ZILIONIS R, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils[J]. Science, 2017, 358(6367): eaal5081. |
| [24] | RYU S, SHIN J W, KWON S, et al. Siglec-F-expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis[J]. J Clin Invest, 2022, 132(12): e156876. |
| [25] | CALCAGNO D M, TAGHDIRI N, NINH V K, et al. Single-cell and spatial transcriptomics of the infarcted heart define the dynamic onset of the border zone in response to mechanical destabilization[J]. Nat Cardiovasc Res, 2022, 1(11): 1039-1055. |
| [26] | WANG X K, XU Y, YU C Q, et al. Periodontitis-related myocardial fibrosis by expansion of collagen-producing SiglecF+ neutrophils[J]. Eur Heart J, 2025, 46(23): 2223-2238. |
| [27] | THORP E B. Cardiac macrophages and emerging roles for their metabolism after myocardial infarction[J]. J Clin Invest, 2023, 133(18): e171953. |
| [28] | WANG W F, LI X, DING X N, et al. Lymphatic endothelial transcription factor Tbx1 promotes an immunosuppressive microenvironment to facilitate post-myocardial infarction repair[J]. Immunity, 2023, 56(10): 2342-2357.e10. |
| [29] | WANG Q X, ISMAHIL M A, ZHU Y J, et al. CD206+ IL-4Rα+ macrophages are drivers of adverse cardiac remodeling in ischemic cardiomyopathy[J]. Circulation, 2025, 152(4): 257-273. |
| [30] | ISMAHIL M A, ZHOU G H, RAJASEKAR S, et al. Splenic CD169+ Tim4+ marginal metallophilic macrophages are essential for wound healing after myocardial infarction[J]. Circulation, 2025, 151(24): 1712-1729. |
| [31] | XU Y, JIANG K, SU F H, et al. A transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium[J]. Cell Rep, 2023, 42(10): 113174. |
| [32] | PORSCH F, MALLAT Z, BINDER C J. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies[J]. Cardiovasc Res, 2021, 117(13): 2544-2562. |
| [33] | HORCKMANS M, BIANCHINI M, SANTOVITO D, et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction[J]. Circulation, 2018, 137(9): 948-960. |
| [34] | MARTíN P, SáNCHEZ-MADRID F. T cells in cardiac health and disease[J]. J Clin Invest, 2025, 135(2): e185218. |
| [35] | ZHUANG R L, MENG Q S, MA X X, et al. CD4+ FoxP3+ CD73+ regulatory T cell promotes cardiac healing post-myocardial infarction[J]. Theranostics, 2022, 12(6): 2707-2721. |
| [36] | WEIRATHER J, HOFMANN U D W, BEYERSDORF N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation[J]. Circ Res, 2014, 115(1): 55-67. |
| [37] | XIA N, LU Y Z, GU M Y, et al. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction[J]. Circulation, 2020, 142(20): 1956-1973. |
| [38] | BLANCO-DOMíNGUEZ R, DE LA FUENTE H, RODRíGUEZ C, et al. CD69 expression on regulatory T cells protects from immune damage after myocardial infarction[J]. J Clin Invest, 2022, 132(21): e152418. |
| [39] | YAN X X, SHICHITA T, KATSUMATA Y, et al. Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction[J]. J Am Heart Assoc, 2012, 1(5): e004408. |
| [40] | JAISWAL S, FONTANILLAS P, FLANNICK J, et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med, 2014, 371(26): 2488-2498. |
| [41] | RETTKOWSKI J, ROMERO-MULERO M C, SINGH I, et al. Modulation of bone marrow haematopoietic stem cell activity as a therapeutic strategy after myocardial infarction: a preclinical study[J]. Nat Cell Biol, 2025, 27(4): 591-604. |
| [42] | ANZAI A, CHOI J L, HE S, et al. The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes[J]. J Exp Med, 2017, 214(11): 3293-3310. |
| [43] | HAMILTON J A. GM-CSF in inflammation[J]. J Exp Med, 2020, 217(1): e20190945. |
| [44] | RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. |
| [45] | TOLDO S, ABBATE A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases[J]. Nat Rev Cardiol, 2024, 21(4): 219-237. |
| [46] | TOLDO S, ABBATE A. The NLRP3 inflammasome in acute myocardial infarction[J]. Nat Rev Cardiol, 2018, 15(4): 203-214. |
| [47] | SAGER H B, HEIDT T, HULSMANS M, et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction[J]. Circulation, 2015, 132(20): 1880-1890. |
| [48] | LI Y J, TU Z Z, CHEN F, et al. Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis[J]. Phytomedicine, 2023, 113: 154743. |
| [49] | LI J, LI S H, WU J, et al. Young bone marrow Sca-1 cells rejuvenate the aged heart by promoting epithelial-to-mesenchymal transition[J]. Theranostics, 2018, 8(7): 1766-1781. |
| [50] | KIM C, KIM H, SIM W S, et al. Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy[J]. Nat Commun, 2024, 15(1): 8481. |
| [51] | WANG L, YU C J, YOU T, et al. Injection of ROS-responsive hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction[J]. Bioact Mater, 2025, 46: 273-284. |
| [52] | JIANG K, XU Y, WANG D D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis[J]. Protein Cell, 2022, 13(5): 336-359. |
| [53] | LYTVYN Y, BJORNSTAD P, UDELL J A, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials[J]. Circulation, 2017, 136(17): 1643-1658. |
/
| 〈 |
|
〉 |